EUVIMEDEUVIMED entdecken
Crossref

Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy

Rongze Sun, Yunshuang Jiao, Jicong Chen, Xiang Pang, Beilin Xue, Jiaqi Yao, Guanpeng Li, Yue Zhang, Jie Yang iD, Lesheng Teng iD

Nano Letters · 2025

DOI: 10.1021/acs.nanolett.5c04210 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Rongze Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun 130012, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neutrophils, Paclitaxel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jilin Province, Department of Science and Technology of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional nanocarriers possess good therapeutic efficacy in the treatment of non-small-cell lung cancer (NSCLC), but usually suffer from high immunogenicity, poor biosafety, and low targeting. In this work, a neutrophil-mediated delivery platform constructed from neutrophils (NEs) and paclitaxel/transforming growth factor-β (TGF-β) siRNA loaded cationic liposome, namely, siTGFβ-PLP-NEs, is fabricated for the combination therapy of NSCLC via synergistic chemo-immunotherapy. siTGFβ-PLP-NEs can be targeted to the tumor site and effectively release paclitaxel and siTGFβ, which is conducive to simultaneously inhibiting the proliferation of tumor cells and the expression of TGF-β. The experimental results demonstrate that siTGFβ-PLP-NEs can prevent the transition of tumor-associated NEs from an anti-tumor (N1) phenotype to a pro-tumor (N2) phenotype, enhance CD8+ T cell infiltration, and reduce regulatory T cell (Treg) infiltration, which provides a great promising combination therapy option to use neutrophil-mediated systems as a general-purpose delivery platform for the treatment of NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeutrophilsPaclitaxelTransforming Growth Factor betaRNA, Small InterferingHumansAnimalsLiposomesImmunotherapyMiceCell Line, TumorDrug Delivery Systems

Stichwörter der Autor:innen

chemo-immunotherapymicroenvironment reversalneutrophil-mediated drug deliverynon-small-cell lung cancertumor delivery efficiency

Substanzen

PaclitaxelLiposomesTransforming Growth Factor betaRNA, Small Interfering

Autor:innen und Institutionen

  • School of Life Sciences, Jilin University, 2699 Qianjin Street, Changchun 130012, P. R. China.

ORCID-Profile: Jie Yang, Lesheng Teng

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jilin Province
  • Department of Science and Technology of Jilin Province
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Sun, R., Jiao, Y., Chen, J., Pang, X., Xue, B., Yao, J., Li, G., Zhang, Y., Yang, J., & Teng, L. (2025). Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c04210

Vancouver

Sun R, Jiao Y, Chen J, Pang X, Xue B, Yao J, et al. Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c04210

BibTeX
@article{Sun2025,
  author = {Sun, Rongze and Jiao, Yunshuang and Chen, Jicong and Pang, Xiang and Xue, Beilin and Yao, Jiaqi and Li, Guanpeng and Zhang, Yue and Yang, Jie and Teng, Lesheng},
  title = {Neutrophil-Mediated Delivery Platforms for Synergistic Chemo-Immunotherapy of Non-Small-Cell Lung Cancer Therapy},
  journal = {Nano Letters},
  year = {2025},
  doi = {10.1021/acs.nanolett.5c04210}
}
Kostenlos starten →